In the first 5, two are for Diabetes.
- Eliquis tops 2023 Medicare spending at $18.3 billion, more than twice the second-ranked drug (Ozempic).
- An aging population—and related conditions like blood clots—are reshaping U.S. healthcare costs.
- The top 35 drugs by Medicare spending are produced by just 20 companies, highlighting the market’s concentration and pricing power.
Four GLP-1 and SGLT2 diabetes drugs—Ozempic, Jardiance, Trulicity, and Farxiga—collectively totaled $29.7 billion.
Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro also double as weight-loss aids, driving demand beyond traditional type-2 diabetes patients.
Revlimid, Humira, and Stelara each exceed $3 billion despite treating fewer than 100,000 beneficiaries each.
Revlimid’s $878 per dose and Stelara’s staggering $26,818 underscore why biologics dominate specialty-drug budgets.
Continue at: https://www.visualcapitalist.com/ranked-americas-most-common-drugs-by-medicare-spending/
The text above is owned by the site above referred.
Here is only a small part of the article, for more please follow the link
Also see:
Manostaxx – Industrial Management Consulting
